Back to the directory
Promakhos Therapeutics
A therapeutics platform for curing inflammatory disorders
- Founded
- 2021
- Status
- Active
- Stage
- Early
- Team size
- 2
- Location
- Boston, MA, USA
- Category
- Biotech & Drug Discovery
- Sector
- Therapeutics
About Promakhos Therapeutics
We are building a platform of bacterial molecules to awaken our body’s innate ability to control inflammation and heal. Our first indication is Crohn’s Disease, which affects over 500,000 Americans at an annual cost of $10B. After Crohn's disease, we are going for type 1 Diabetes and Multiple Sclerosis.
Therapeutics
Federal research funding
1 NIH award totalling $271,865, FY2023.
- Preclinical validation of small molecule immunomodulators for the treatment of Crohn's disease
Source: NIH RePORTER.
Securities filings
1 Form D filing on record, 2022.
Filed as Promakhos Therapeutics Inc.
Source: SEC EDGAR. Form D reports an exempt offering; it does not confirm funds raised.
Company data compiled and maintained by Healthcare Discovery.
